Shino Manabe

Dr. Shino Manabe

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2010 in Journal of Chemical Theory and Computation
Verified
Journal Article
Closed access
HSHiroko Satoh
Hiroko Satoh
HHHalvor S. Hansen
Halvor S. Hansen
SMShino Manabe
Shino Manabe
WGWilfred F. van Gunsteren
Wilfred F. van Gunsteren
PHPhilippe H. Hünenberger
Philippe H. Hünenberger

28 July 2006 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SMShino Manabe
Shino Manabe
KIKazuyuki Ishii
Kazuyuki Ishii
YIYukishige Ito
Yukishige Ito

28 February 2003 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
IMIchiro Matsuo
Ichiro Matsuo
MWMegumi Wada
Megumi Wada
SMShino Manabe
Shino Manabe
YYYoshiki Yamaguchi
Yoshiki Yamaguchi
KOKeisuke Otake
Keisuke Otake
YIYukishige Ito
Yukishige Ito

1 January 1996 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
GSGilbert Stork
Gilbert Stork
FWFrederick West
Frederick West
HLHee Yoon Lee
Hee Yoon Lee
RIRichard C. A. Isaacs
Richard C. A. Isaacs
SMShino Manabe
Shino Manabe

1 August 2018 in Journal of Controlled Release
Verified
Journal Article
Open access
RTRyo Tsumura
Ryo Tsumura
SMShino Manabe
Shino Manabe
HTHiroki Takashima
Hiroki Takashima
Yoshikatsu KogaYoshikatsu Koga
Yoshikatsu Koga
MYMasahiro Yasunaga
Masahiro Yasunaga
YMYasuhiro Matsumura
Yasuhiro Matsumura
Antibody-drug conjugates (ADCs) are currently considered to be promising agents for cancer therapy. However, especially in solid tumors, the uneven distribution of ADCs would decrease their efficacy in clinical studies. We suggest that in addition to optimizing ADC components, such as the linker structure and anticancer agent, it is necessary to consider the distribution of the ADC within tumor tissue. In this study, we established three kinds of anti-tissue factor (TF) ADCs: 1849ADC with a low kd, 444ADC with an intermediate kd, and 1084ADC with a high kd. All three of the anti-TF ADCs exhibited almost the same in vitro cytotoxicity and pharmacological and biochemical characteristics, although the binding kinetics parameters differed. In vivo, all ADCs exerted equivalent antitumor effects against small BxPC3 tumors. However, on larger BxPC3 tumors, 1084ADC (higher kd) exerted higher antitumor activity than 1849ADC (lower kd). Furthermore, immunofluorescence staining indicated that 1084ADC was distributed throughout the whole tumor, whereas 1849ADC was mainly localized close to tumor vessels. We conclude that the ADC with a higher kd increased the antitumor effect of because it penetrated and distributed evenly throughout the entire solid tumor. These findings highlight the importance of the kd of a mAb in ADC design.

13 July 2011 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
MYMasahiro Yasunaga
Masahiro Yasunaga
SMShino Manabe
Shino Manabe
DTDavid Tarin
David Tarin
YMYasuhiro Matsumura
Yasuhiro Matsumura